Status:
COMPLETED
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
Lead Sponsor:
Novartis
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE4
Brief Summary
Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, pla...
Eligibility Criteria
Inclusion
- Clinical diagnosis of mild to moderate Alzheimer's disease
- Must be able to swallow capsule/tablet
- Must have a caregiver who is available to attend all study visits
Exclusion
- Digestive problems related to peptic ulcer
- Experienced a heart attack or stroke in the last 6 months
- Serious/unstable asthma or severe pulmonary (lung) disease
- On current treatment with a blood thinner
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00104442
Start Date
October 1 2003
End Date
April 1 2006
Last Update
December 21 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936